Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.8652W HIGH $17.40
Volume
35.03 K
Value Traded
3.02 M
Short % Float
7.83%
-3.24%Week
-24.49%1 Month
-33.85%3 Month
+1.7%6 Month
-97.03%5 Year
-99.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
115.29 M
EPS (TTM)
-6.82
P/E Ratio
-
Ent. Value
108.60 M
Total Shares
12.97 M
Float Shares
9.83 M
Insiders
14.01%
Institutions
36.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
KZIA Catalyst Timeline
Dated clinical, regulatory and corporate events for Kazia Therapeutics Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kazia Therapeutics Limited
484Total events
26Upcoming
111Tier-1 (high impact)
2017 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedPaxalisibTrial
Sovargen doses first patient in Phase 1b/2a trial of paxalisib for FCD T2 and TSC
intractable epilepsy associated with focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC)source ↗
▲Milestone PaymentPaxalisibCorporate
$2 million development milestone payment to Kazia triggered by first patient dosing
intractable epilepsy associated with focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC)source ↗
▲First Patient DosedPaxalisibTrial
First patient dosed in Arm A of PNOC035 evaluating paxalisib plus gemcitabine in recurrent/progressive AT/RT
recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT)source ↗
▲Preclinical PoCPaxalisibPreclinical
Adding paxalisib to immunotherapy reduced tumor volume by additional 50% vs immunotherapy alone
MSS/pMMR colorectal cancersource ↗
●Composition Patent FiledPaxalisibIP / Competition
New patent filing covering paxalisib's potential use in colorectal cancer
colorectal cancersource ↗
▲Patent GrantedPaxalisibIP / Competition
Provisional patent application filed
HR+/HER2- breast cancersource ↗
▲Patent GrantedIP / Competition
Provisional patent application filed for HR+ breast cancer findings
HR+/HER2- breast cancersource ↗
●Protocol AmendmentPaxalisibTrial
Protocol amendment to add three-arm expansion to ongoing TNBC trial
HR+/HER2- metastatic breast cancersource ↗
▲Topline ReadoutPaxalisibClinical Data
Initial six patients in Phase 1b TNBC trial show 100% clinical benefit rate
advanced triple-negative breast cancersource ↗
▲Topline ReadoutPaxalisibClinical Data
Initial six patients in Phase 1b trial show 100% clinical benefit rate
advanced triple-negative breast cancersource ↗
●Composition Patent FiledPaxalisibIP / Competition
Filing of provisional patent for perioperative therapeutic strategy to prevent metastatic recurrence in TNBC
high-risk early-stage triple-negative breast cancersource ↗
▲Preclinical PoCPaxalisibPreclinical
Preclinical data show paxalisib reduces residual disease and local recurrence by 95% and lung metastatic burden by 40% in TNBC model
triple-negative breast cancersource ↗
▲Biomarker DataPaxalisibClinical Data
Translational studies show paxalisib completely disrupts CTC clusters in ex vivo TNBC patient samples
triple-negative breast cancersource ↗
▲Interim Efficacy DataPaxalisibClinical Data
Ongoing Phase Ib study of paxalisib in combination with pembrolizumab and chemotherapy in advanced TNBC shows encouraging preliminary findings including objective responses and CTC cluster disruption
triple-negative breast cancersource ↗
●Composition Patent FiledIP / Competition
Filing of provisional patent application for novel strategy to prevent metastatic recurrence in TNBC
triple-negative breast cancersource ↗
▲Enrollment UpdatePaxalisibTrial
Planned enrollment increased from 12 to 36 patients in Phase 1b trial of paxalisib in advanced TNBC
advanced triple negative breast cancersource ↗
●AbstractPaxalisibPresentation
Abstracts withdrawn from ASCO 2026 to protect intellectual property
advanced triple negative breast cancersource ↗
▲Preclinical PoCPaxalisibPreclinical
Preclinical study published in Molecular Cancer Therapeutics demonstrating dual PI3K/mTOR inhibition with paxalisib altered tumor cell state and immune signaling in TNBC models
triple negative breast cancersource ↗
▲Partnership / LicenseCorporate
In-licensed SETDB1-targeted epigenetic drug development platform from QIMR Berghofer
oncologysource ↗
◆Oral PresentationNDL2Presentation
Presentation of NDL2 dataset at oncology scientific meeting
immunotherapy-refractory solid tumorssource ↗
●Enrollment UpdatePaxalisibTrial
Two additional clinical sites to be activated by April 2026
metastatic triple-negative breast cancersource ↗
●IND Enabling CompleteNDL2Preclinical
IND-enabling studies expected to commence within six months
advanced breast cancer, non-small cell lung cancersource ↗
▲Preclinical PoCNDL2Preclinical
Compelling preclinical and translational data for NDL2 announced
immunotherapy-refractory solid tumorssource ↗
▲Primary Endpoint MetPaxalisibClinical Data
Partial response with complete resolution of target lesion in Patient 2
metastatic triple-negative breast cancersource ↗
◆Oral PresentationPresentation
Kazia Therapeutics to participate in J.P. Morgan Healthcare Conference week meetings
◆Quarterly UpdateNDL2Corporate
Corporate presentation update including NDL2 program updates
immunotherapy-refractory solid tumorssource ↗
◆Topline ReadoutPaxalisibClinical Data
Anticipated clinical and translational update from Phase 1b trial of paxalisib in TNBC
advanced triple-negative breast cancer (TNBC)source ↗
▲Primary Endpoint MetPaxalisibClinical Data
Complete metabolic response confirmed in Patient 3
metastatic triple-negative breast cancersource ↗
▲Full ResultsPaxalisibClinical Data
Complete metabolic response in stage IV TNBC patient under expanded access and two partial responses in ongoing Phase 1b study
triple negative breast cancersource ↗
●IND Enabling CompleteNDL2Preclinical
Initiate IND-enabling preclinical studies for NDL2 PD-L1 degrader program
cancersource ↗
▲AdCom CancelledAdvisory Committee
Nasdaq Hearings Panel hearing cancelled as moot due to regained compliance
◆Oral PresentationPaxalisibPresentation
Phase 1b study of paxalisib with olaparib or pembrolizumab/chemotherapy in advanced breast cancer
breast cancersource ↗
●Poster PresentationPaxalisibPresentation
Two presentations at 2025 San Antonio Breast Cancer Symposium (SABCS) on paxalisib activity
HER2-positive metastatic breast cancer and TNBCsource ↗
◆Oral PresentationPaxalisibPresentation
Poster PS5-08-04: Phase 1b study of paxalisib with pembrolizumab/chemotherapy in advanced breast cancer
triple-negative breast cancer (TNBC)source ↗
▲Topline ReadoutPaxalisibClinical Data
Early longitudinal biomarker data from first patient in PaxPlus-ABC
advanced breast cancer (TNBC)source ↗
▲Full ResultsPaxalisibClinical Data
Ex-vivo data in HER2+ patients demonstrating immune reinvigoration and CTC cluster disruption
HER2-positive metastatic breast cancersource ↗
◆Oral PresentationPresentation
Liquid Biopsy Tracking of PI3K-mTOR Residual Disease Signatures in Metastatic Breast Cancer
breast cancersource ↗
▼Equity OfferingCorporate
$50 million private placement of equity securities led by healthcare-dedicated institutional investors
◆Oral PresentationPresentation
From bench to bedside: targeting epigenetic pathways to overcome metastasis and immunotherapy resistance in TNBC
triple-negative breast cancersource ↗
▲Additional DataPaxalisibClinical Data
Initial immune-complete response (iCR) in metastatic TNBC in expanded-access setting
metastatic triple-negative breast cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How KZIA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | NDL2 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D36 / 100
Pipeline Score
$41M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.3x
rNPV / MCap
Top 51%
Micro Cap(rank 336 of 658)
Percentile Rank
Kazia Therapeutics Limited faces pipeline headwinds (36/100), with $572M risk-adjusted pipeline value, led by Paxalisib in CDK Gene Mutation (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Paxalisib Small moleculeNCT03994796 | CDK Gene Mutation | Phase 2 | ACTIVE NOT_RECRUITING | 50 | Jun 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every KZIA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| paxalisib Fast TrackOrphanRare Pediatric | advanced triple-negative breast cancer | Phase 1b | 2026-08-27 | clinical benefit rate: 100%; objective response rate: 83%; complete response: 1; partial responses: 4; stable disease: 1; median reduction CTC clusters: 83%; median reduction terminally exhausted T cells: 51%Read More | Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Coffey Steven R. S.Director | Grant/Award | 100,000 100,000 held | $0.00 | 01/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KZIA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in KZIA for Q2 2026. | ||||
KZIA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KZIA ranks across every disease it competes in
Competitive Position is a premium feature
See how KZIA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKZIA News
KZIAKazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Kazia Therapeutics announced that Sovargen Co. has dosed the first patient in a Phase 1b/2a trial of paxalisib for treating intractable epilepsy related to focal cortical dysplasia type 2 and tuberous sclerosis complex. This milestone triggers a $2 million payment to Kazia. The trial aims to explore paxalisib's potential in addressing significant unmet medical needs in these rare disorders.
Read more →KZIAKazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
Kazia Therapeutics has announced the dosing of the first patient in the PNOC035 clinical study, evaluating paxalisib combined with gemcitabine for recurrent pediatric AT/RT. This Phase 2 study aims to provide new treatment options for a cancer with no approved therapies. The combination has shown promising preclinical results, significantly increasing median survival.
Read more →KZIA▼ -8.3%on this news
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Kazia Therapeutics reported promising preclinical data for paxalisib, which demonstrated a 52% reduction in tumor burden in MSS/pMMR colorectal cancer models. The addition of pembrolizumab further enhanced tumor reduction by 50%. The company plans to initiate a Phase 2 clinical trial to evaluate paxalisib's efficacy in immunotherapy-resistant colorectal cancer. The treatment was well tolerated, showing no significant toxicity.
Read more →KZIA▼ -8.3%on this newsshared move
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Kazia Therapeutics is expanding its ongoing clinical trial of paxalisib into HR+/HER2- breast cancer, supported by promising preclinical data. The trial will evaluate paxalisib combined with standard therapies and aims to address significant unmet medical needs. The first patient is expected to be enrolled by the end of 2026, with full enrollment anticipated by 2027.
Read more →KZIA▼ -8.3%on this newsshared move
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Kazia Therapeutics Limited has successfully closed an oversubscribed public offering, generating approximately $40 million in upfront gross proceeds, with potential total proceeds of $120 million. The offering includes American Depositary Shares and warrants linked to clinical milestones for breast cancer treatments. Kazia plans to utilize the funds primarily for the clinical development of its lead asset, paxalisib.
Read more →KZIA▼ -19.6%on this newsshared move
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
Kazia Therapeutics Limited has announced a public offering priced at $15.50 per American Depositary Share, aiming to raise up to $120 million. The offering includes warrants and is expected to close by August 31, 2026. Proceeds will primarily fund clinical development of paxalisib for various oncology indications. The company has ongoing trials and has received multiple designations from the FDA.
Read more →KZIA▼ -19.6%on this newsshared move
Kazia Therapeutics Limited Announces Proposed Public Offering
Kazia Therapeutics Limited has announced a proposed public offering of American Depositary Shares (ADSs) and warrants to fund the clinical development of its lead asset, paxalisib. The offering is intended to support ongoing studies in triple-negative breast cancer and HR+/HER2- breast cancer. The completion of the offering is subject to market conditions, and there are associated risks regarding clinical milestones and regulatory approvals.
Read more →KZIA▼ -19.6%on this newsshared move
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Kazia Therapeutics reported a 100% clinical benefit rate in six patients with advanced triple-negative breast cancer treated with paxalisib. Five patients showed significant tumor reductions, including one complete response. The treatment demonstrated a favorable safety profile, with no serious adverse events. The ongoing Phase 1b trial aims to further explore paxalisib's efficacy in combination with other therapies.
Read more →KZIAKazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
Kazia Therapeutics has filed a provisional patent for a new therapeutic strategy aimed at preventing metastatic recurrence in high-risk early-stage triple-negative breast cancer (TNBC). Supported by promising preclinical data, the strategy involves the use of paxalisib, which has shown a significant reduction in residual disease and lung metastasis. The company is looking to broaden the clinical development of paxalisib based on these findings.
Read more →KZIA▼ -6.1%on this news
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
Kazia Therapeutics has appointed James Levine as Chief Financial Officer, effective June 1, 2026. Levine brings over 20 years of experience in financial leadership within the biotech sector. His role is expected to support Kazia's advancement of its lead asset, paxalisib, and the development of its oncology pipeline. The company is targeting multiple cancer indications with promising clinical trials underway.
Read more →KZIA▼ -8.4%on this news
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics has announced an expansion of its ongoing Phase 1b trial for paxalisib in advanced triple negative breast cancer, increasing patient enrollment from 12 to 36. This decision follows positive safety and tolerability data. The trial aims to assess the efficacy of paxalisib in combination with pembrolizumab and chemotherapy, with updates expected throughout 2026 and 2027.
Read more →KZIANASDAQ: KZIA | X: @KaziaTx Beyond Inhibition. Reprogramming Cancer Control. 2026 Corporate Overview April 2026 This presentation contains forward - looking statements, which can generally be identified as such by the use
Kazia Therapeutics is a clinical-stage oncology company focused on developing next-generation therapies for high-need cancers. The company highlighted its lead asset, paxalisib, a dual PI3K/mTOR inhibitor, and other candidates like NDL2 and EVT801 in its corporate overview. With ongoing trials and approximately $46 million in cash, Kazia is positioned to continue its research and clinical programs into 2029. The company aims to redefine cancer treatment by going beyond conventional methods and targeting fundamental drivers of cancer biology.
Read more →KZIA▲ +5.7%on this news
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Kazia Therapeutics has appointed Dr. Sudha Rao as Chief Scientific Officer to lead its oncology platform. Dr. Rao, a pioneer in epigenetic therapies, will oversee research and development, focusing on advancing Kazia's pipeline, including paxalisib and novel PD-L1 degradation strategies. Her leadership is expected to strengthen Kazia's integrated oncology strategy.
Read more →KZIA▲ +5.2%on this news· ran to +23% by day 3shared move
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
Kazia Therapeutics has in-licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The lead candidate, MSETC, aims to restore immune signaling in tumors resistant to immunotherapy. This program is part of Kazia's strategy to address cancer treatment resistance through innovative therapies. The SETDB1 program is currently in preclinical development with a clear path toward IND-enabling studies.
Read more →About Kazia Therapeutics Limited
Headquarters140 WICKS RD, NEW SOUTH WALES 2113, C3, 2113
BIOPHARMAWATCH ELITE PLUS
Trade the next KZIA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime